D. A. Rothrock, M. R. Abbott, N. G. Maynard, R. Alley, F. Muller-karger, P. G. Brewer, ...
3.1.1 Organization of this chapter 117 3.1.2 Oceans and climate 117 3.1.3 Oceans and humanity 117
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects (1998)
Ridge, S.A., Sludden, J., Brown, O., Robertson, L., Wei, X., Sapone, A., ...
Thesis (Ph. D.)--Purdue University, 1965.
Loracarbef concentrations in middle ear fluid.
Kusmiesz, H, Shelton, S, Brown, O, Manning, S, Nelson, J D
Loracarbef concentrations in plasma and middle ear fluid (MEF) were measured in specimens obtained approximately 2 h after doses of 7.5 or 15 mg/kg. The mean +/- standard deviation concentrations in...
Loracarbef concentrations in middle ear fluid.
Kusmiesz, H, Shelton, S, Brown, O, Manning, S, Nelson, J D
Loracarbef concentrations in plasma and middle ear fluid (MEF) were measured in specimens obtained approximately 2 h after doses of 7.5 or 15 mg/kg. The mean +/- standard deviation concentrations in...
Mutations at codon 974 of the DPYD gene are a rare event.
Ridge, S. A., Brown, O., McMurrough, J., Fernandez-Salguero, P., Evans, W. E., Gonzalez, F. J., ...
A mutation at codon 974 of the dihydropyrimidine dehydrogenase (DPD) gene was previously described in a cancer patient with undetectable DPD enzyme activity who experienced severe toxicity when...
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., ...
Individuals with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may experience severe life-threatening toxicity when treated with 5-fluorouracil (5-FU). As routine measurement of...